Aarti Pharmalabs schedules Q4 FY26 earnings call

Aarti Pharmalabs Limited has scheduled an earnings conference call to discuss its financial results for the fourth quarter of the fiscal year 2026. The meeting is set to take place on Tuesday, May 26, 2026, at 4:00 PM IST. The announcement was made in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015.

The conference call is open to investors and analysts interested in the company's performance for the quarter ending March 31, 2026. Aarti Pharmalabs Limited has provided a registration link for participants to join the session virtually.

Management Participants

The discussion will feature key members of the company's leadership team. The following executives are scheduled to participate in the call:

Mr. Rashesh Gogri - Chairman
Mrs. Hetal Gogri Gala - Vice Chairperson and Managing Director
Mr. Piyush Lakhani - Chief Financial Officer

Conference Call Details

Investors and analysts are requested to pre-register for the call using the provided URL to ensure access. The logistical details for the event are outlined below:

Detail	Information
Date	Tuesday, May 26, 2026
Time	4:00 PM IST
Platform	Zoom Webinar
Registration Link	Zoom Registration

For further information regarding the conference call, participants may contact Mr. Sidharth Jain via email at sidharth.jain@ysil.in or by phone at +91 96191 63164.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.73%	-1.68%	+0.43%	-1.07%	-18.06%	+143.10%

Aarti Pharmalabs Limited has informed the stock exchanges that the Board of Directors meeting, originally scheduled for Monday, May 18, 2026, has been postponed and rescheduled to Monday, May 25, 2026. The postponement intimation was issued on May 14, 2026, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, referencing the earlier intimation dated May 11, 2026.

Revised Board Meeting Details

The rescheduled Board meeting will address the same agenda items as originally planned. The following table summarises the updated meeting details:

Parameter:	Details
Original Meeting Date:	Monday, May 18, 2026
Revised Meeting Date:	Monday, May 25, 2026
Regulatory Reference:	Regulation 29, SEBI (LODR) Regulations, 2015
Agenda Item 1:	Audited Financial Results for Q4 and FY ended March 31, 2026
Agenda Item 2:	Consider and recommend Final Dividend, if any, for FY ended March 31, 2026
Postponement Intimation Date:	May 14, 2026

Financial Results and Dividend Consideration

The Board will consider and approve the audited financial results of the company for the quarter and financial year ended March 31, 2026, after these results are reviewed by the Audit Committee of the Board. Additionally, the Board will deliberate on whether to recommend a final dividend for the financial year ended March 31, 2026, subject to applicable approvals.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of Aarti Pharmalabs had been closed from April 01, 2026. Following the postponement of the Board meeting, the Trading Window shall now remain closed until 48 hours after the declaration of the financial results, i.e., till May 27, 2026.

The postponement intimation was signed by Jeevan Mondkar, Company Secretary and Legal Head (ICSI M. No. A22565), on behalf of Aarti Pharmalabs Limited.